Literature DB >> 15546622

The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression.

Neri Minsky1, Moshe Oren.   

Abstract

Histone modifications play a pivotal role in regulating transcription and other chromatin-associated processes. In yeast, histone H2B monoubiquitylation affects gene silencing. However, mammalian histone ubiquitylation remains poorly understood. We report that the Mdm2 oncoprotein, a RING domain E3 ubiquitin ligase known to ubiquitylate the p53 tumor suppressor protein, can interact directly with histones and promote in vitro monoubiquitylation of histones H2A and H2B. Moreover, Mdm2 induces H2B monoubiquitylation in vivo. Endogenous Mdm2 is tethered in vivo, presumably via p53, to chromatin comprising the p53-responsive p21(waf1) promoter, and Mdm2 overexpression enhances protein ubiquitylation in the vicinity of a p53 binding site within that promoter. Moreover, when recruited to a promoter in the absence of p53, Mdm2 can repress transcription dependently on its RING domain, suggesting that its E3 activity contributes to repression. Histone ubiquitylation may thus constitute a novel mechanism of transcriptional repression by Mdm2, possibly underlying some of its oncogenic activities.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15546622     DOI: 10.1016/j.molcel.2004.10.016

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  85 in total

Review 1.  The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis.

Authors:  Ali Shilatifard
Journal:  Annu Rev Biochem       Date:  2012       Impact factor: 23.643

2.  MdmX is required for p53 interaction with and full induction of the Mdm2 promoter after cellular stress.

Authors:  Lynn Biderman; Masha V Poyurovsky; Yael Assia; James L Manley; Carol Prives
Journal:  Mol Cell Biol       Date:  2012-01-30       Impact factor: 4.272

3.  MDM2 recruitment of lysine methyltransferases regulates p53 transcriptional output.

Authors:  Lihong Chen; Zhenyu Li; Aleksandra K Zwolinska; Matthew A Smith; Brittany Cross; John Koomen; Zhi-Min Yuan; Thomas Jenuwein; Jean-Christophe Marine; Kenneth L Wright; Jiandong Chen
Journal:  EMBO J       Date:  2010-06-29       Impact factor: 11.598

Review 4.  The p53 orchestra: Mdm2 and Mdmx set the tone.

Authors:  Mark Wade; Yunyuan V Wang; Geoffrey M Wahl
Journal:  Trends Cell Biol       Date:  2010-02-19       Impact factor: 20.808

Review 5.  Balance of Yin and Yang: ubiquitylation-mediated regulation of p53 and c-Myc.

Authors:  Mu-Shui Dai; Yetao Jin; Jayme R Gallegos; Hua Lu
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715

6.  Histone H2A monoubiquitination represses transcription by inhibiting RNA polymerase II transcriptional elongation.

Authors:  Wenlai Zhou; Ping Zhu; Jianxun Wang; Gabriel Pascual; Kenneth A Ohgi; Jean Lozach; Christopher K Glass; Michael G Rosenfeld
Journal:  Mol Cell       Date:  2008-01-18       Impact factor: 17.970

7.  Cooperative regulation of p53 by modulation of ternary complex formation with CBP/p300 and HDM2.

Authors:  Josephine C Ferreon; Chul Won Lee; Munehito Arai; Maria A Martinez-Yamout; H Jane Dyson; Peter E Wright
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-08       Impact factor: 11.205

8.  Lysine-independent turnover of cyclin G1 can be stabilized by B'alpha subunits of protein phosphatase 2A.

Authors:  Hongyun Li; Koji Okamoto; Melissa J Peart; Carol Prives
Journal:  Mol Cell Biol       Date:  2008-11-03       Impact factor: 4.272

9.  The Lats2 tumor suppressor augments p53-mediated apoptosis by promoting the nuclear proapoptotic function of ASPP1.

Authors:  Yael Aylon; Yaara Ofir-Rosenfeld; Norikazu Yabuta; Eleonora Lapi; Hiroshi Nojima; Xin Lu; Moshe Oren
Journal:  Genes Dev       Date:  2010-11-01       Impact factor: 11.361

10.  Acetylation is indispensable for p53 activation.

Authors:  Yi Tang; Wenhui Zhao; Yue Chen; Yingming Zhao; Wei Gu
Journal:  Cell       Date:  2008-05-16       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.